TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06783231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identifying with the aggressor
Description: The IWA lab task consists 10 min audio recorded story, portraying a romantic relationship between two women (Lori and Sophia), in which one of them (Lori - the perpetrator) is being aggressive towards the other (Sophia - the victim). The story was carefully designed to align with ethical considerations - it is non-graphic, contains no severe acts of violence, and mostly describes a romantic power dynamic which may be considered abusive or toxic. The three groups of participants will receive different instructions before listening to the audio recording. The 'identification with the aggressor' group will be asked to try to identify, understand and adopt the point of view of Lori (the perpetrator)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Identifying with the victim
Description: The IWA lab task consists 10 min audio recorded story, portraying a romantic relationship between two women (Lori and Sophia), in which one of them (Lori - the perpetrator) is being aggressive towards the other (Sophia - the victim). The story was carefully designed to align with ethical considerations - it is non-graphic, contains no severe acts of violence, and mostly describes a romantic power dynamic which may be considered abusive or toxic. The three groups of participants will receive different instructions before listening to the audio recording. The 'identification with the victim' group will be asked to try to identify, understand and adopt the point of view of Sophia (the victim)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral
Description: The IWA lab task consists 10 min audio recorded story, portraying a romantic relationship between two women (Lori and Sophia), in which one of them (Lori - the perpetrator) is being aggressive towards the other (Sophia - the victim). The story was carefully designed to align with ethical considerations - it is non-graphic, contains no severe acts of violence, and mostly describes a romantic power dynamic which may be considered abusive or toxic. The three groups of participants will receive different instructions before listening to the audio recording. The control group will be asked to pay attention to the story's details and to try and remember as much details as they can.
Study: NCT01882413

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01246999

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Live attenuated Influenza vaccine
Description: 0.2 mL dose delivered through nasal spray, 0.1 ml in each nostril, 2 doses separated by 28 days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine
Description: .25 mL given intramuscularly to children 24 to 36 months of age, 2 doses given 28 days apart, .5 mL given intramuscularly to children 37 months to 9 years of age, 2 doses given 28 day s apart.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV followed by LAIV
Description: TIV .25 mL given intramuscularly to children 24 to 36 months of age or .5 mL given intramuscularly to children 37 months to 9 years of age, followed by FluMist 0.2 mL delivered by nasal spray (.1 mL in each nostril)28 days later
Study: NCT06548633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar Vertebral Mobilisation
Description: The participants received Vertebral Lumbar Mobilisations, these were posterior-anterior central vertebral pressures (PACVPs) for four sets of 30 seconds, with up to 30s between each, at a grade III amplitude.
Study: NCT04298879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI376
Description: IBI376 20 mg po. once daily for 8 weeks ，followed by 2.5mg once daily
Study: NCT01246999

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LAIV followed by TIV
Description: LAIV .2 mL given through nasal spray (.1 mL in each nostril) Followed by TIV .25 mL given intramuscularly to children 24 to 25 months of age or .5 mL given intramuscularly to children 36 months to 9 years of age 28 days later
Study: NCT01530581

Intervention type: PROCEDURE
Group type: OTHER
Intervention: G-PB Transplant
Description: G-PB Transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: G-BM Transplant
Description: G-BM Transplant
Study: NCT02288169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPE
Description: We propose to test a brief, effective intervention with outpatients in a cancer center, with the goal of teaching patients symptom management skills for self-identified symptoms of highest priority to patients. The proposed randomized clinical trial will test the efficacy of the COPE intervention with patients with symptoms of moderate to high intensity, distress, frequency or interference with their lives as a result of their cancer.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Support/Attention Control
Description: The attention control group will receive supportive visits from the research team at the cancer center and subsequent meetings during clinic visits plus 2 subsequent supportive telephone calls
Study: NCT01606371

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally
Study: NCT03423810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine
Description: Participants will be asked to take pills two times per day for 6 weeks. This is a dose increasing study with potential doses ranging from 5 mg two times per day to 50 mg two times per day.
Study: NCT02473965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGIV-C
Description: Run-Phase: 1 loading dose of 2 g/kg IGIV-C and 2 maintenance doses of 1 g/kg IGIV-C~Corticosteroid Tapering/IGIV-C Maintenance Phase: 1 g/kg IGIV-C every 3 weeks for up to 36 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00733395

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tart Cherry Juice
Description: Participants will ingest 10.5 fl oz of cherry juice twice a day for 7 days prior to the race, and the day of the race (8 days total).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fruit juice
Description: Participants will ingest 10.5 fl oz of fruit juice twice a day for 7 days prior to the race, and the day of the race (8 days total), which will serve as a 'placebo' juice.
Study: NCT01792531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent training group
Description: The More \& Less group will focus on how to use positive parenting practices (e.g., reinforcement/encouragement, limit setting, monitoring, problem-solving, positive involvement, and emotion regulation) instead of ineffective practices (e.g., coercive behavior, negative reciprocity, escalation, and negative reinforcement). Using a parent-group approach to intervention administration, each of the twelve More \& Less sessions (1.5h/wk) consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments. The information and procedures will be tailored to focus on changes in the home environment, mostly related to child food habits and physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent training group
Description: The More \& Less group will focus on how to use positive parenting practices (e.g., reinforcement/encouragement, limit setting, monitoring, problem-solving, positive involvement, and emotion regulation) instead of ineffective practices (e.g., coercive behavior, negative reciprocity, escalation, and negative reinforcement). Using a parent-group approach to intervention administration, each of the twelve More \& Less sessions (1.5h/wk) consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments. The information and procedures will be tailored to focus on changes in the home environment, mostly related to child food habits and physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard treatment with focus on lifestyle
Description: The treatment will be provided by local pediatricians in outpatient pediatric departments and will be based on lifestyle modifications, as recommended in the action plan for Stockholm County.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent training group with booster sessions
Description: Parent training group with additional booster sessions at 8-week intervals for the following year.
Study: NCT00487825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab (investigational)
Description: Canakinumab was supplied in 6 mL colorless glass vials each containing nominally 150 mg canakinumab (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo was supplied in form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Methotrexate (MTX) was supplied in tablet form, each of 2.5 mg strength.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate (MTX)
Description: Methotrexate (MTX) was supplied in tablet form, each of 2.5 mg strength.
Study: NCT01507649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-based cognitive-behavioral intervention
Description: The intervention is based on the cognitive-behavioral approach. It consists of five, 30-minutes sessions delivered weekly from postpartum week one to week five via telephone.
Study: NCT04339712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: In case of diagnosis of MAS treatment with anakinra

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: In case of diagnosis of immune dysregulation treatment with tocilizumab
Study: NCT01562223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motexafin gadolinium
Study: NCT05609604

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Electric current will be delivered to the pre-frontal cortex for 30 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Shame- No current
Study: NCT04638556

Intervention type: DIAGNOSTIC_TEST
Intervention: lncRNA detection
Description: The lncRNAs in the plasma of three groups of patients will be tested.

Intervention type: DIAGNOSTIC_TEST
Intervention: lncRNA detection
Description: The lncRNAs in the plasma of three groups of patients will be tested.

Intervention type: DIAGNOSTIC_TEST
Intervention: lncRNA detection
Description: The lncRNAs in the plasma of three groups of patients will be tested.
Study: NCT03180931

Intervention type: DEVICE
Intervention: Bioresorbable vascular scaffold
Description: No study specific procedures will be applied. Optical coherence tomography recordings at the time of very late scaffold thrombosis were obtained during clinical routine with one of the commercially available and approved optical coherence tomography consoles and catheters. The analysis will be conducted at the Core laboratory at Bern University Hospital, Bern, Switzerland using a systematic and validated approach.~Every participant will be coded by getting a number (pseudonym) in the local institutes. In the Core Laboratory, data will be further coded to ensure anonymity of the participants.
Study: NCT03102749

Intervention type: OTHER
Intervention: metacholine provocation test and CT-scan low dose
Description: Investigators perform a metacholine provocation test where expiratory CT slices were acquired at each dose

Intervention type: OTHER
Intervention: metacholine provocation test and CT-scan low dose
Description: Investigators perform a metacholine provocation test where expiratory CT slices were acquired at each dose
Study: NCT02646787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Virtual Reality
Description: The subject is actively engaged in using virtual reality during a painful burn wound care session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passive Virtual Reality
Description: The subject is passively engaged in using virtual reality during a painful burn wound care session.
Study: NCT03126071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: Raltitrexed:3mg/m2,iv 15min,d1,q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: Raltitrexed:3mg/m2,iv 15min,d1,q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan:250mg/m2,iv 90min,d1,q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin:130mg/m2,iv 120min,d1,q3w.
Study: NCT03102749

Intervention type: OTHER
Intervention: metacholine provocation test and CT-scan low dose
Description: Investigators perform a metacholine provocation test where expiratory CT slices were acquired at each dose
Study: NCT03126071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab:75mg/kg,iv 30min,d1,q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab:75mg/kg,iv 30min,d1,q3w.
Study: NCT02688764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21 (Velphoro®)
Description: During Stage 1 (Open-Label Dose Titration; up to 10 weeks), PA21 subjects will receive PA21 at a starting dose based on their age. Dose of PA21 will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.~During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Acetate (Phoslyra®)
Description: During Stage 1 (Open-Label Dose Titration; up to 10 weeks), Phoslyra subjects will receive Phoslyra either at a starting dose based on their weight or, if considered more appropriate by the Investigator, at an equivalent dose of their previous phosphate binder (PB), calcium-based or sevelamer. Dose of Phoslyra will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.~During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2.
Study: NCT01342445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisdexamfetamine dimesylate
Description: 30-mg, 50-mg, 70-mg administered for one week in context of double-blind, placebo-controlled crossover design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03589157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug-coated balloon (DCB) combined with spot stenting of drug-eluting stent (DES)
Description: using drug-coated balloon (DCB) combined with spot stenting of drug-eluting stent (DES) for treating diffuse coronary artery lesions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug-coated balloon (DCB) combined with second-generation of drug-eluting stent (DES)
Description: using drug-coated balloon (DCB) combined with second-generation DES for treating diffuse coronary artery lesions
Study: NCT01331707

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity (Zotarolimus-eluting stent)
Description: Third generation drug-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Promus Element (Everolimus-eluting stent)
Description: Third generation drug-eluting stent
Study: NCT03955588

Intervention type: DIAGNOSTIC_TEST
Intervention: aCGH
Study: NCT02102672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Study: NCT01493115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine HOE901
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine HOE901
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine HOE901
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine - New formulation HOE901
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine - New formulation HOE901
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine - New formulation HOE901
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study: NCT02568397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Administered orally
Study: NCT01060397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended Brief Intervention
Description: Frames motivational interviewing approach

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Usual care
Study: NCT04397211

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-derived FFR
Description: The percutaneous coronary intervention using drug-eluting stent will be indicated according to following criteria in the Angiography-derived FFR-guided strategy arm~\*Criteria for revascularization: Angiography-derived FFR ≤ 0.80

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVUS
Description: The percutaneous coronary intervention using drug-eluting stent will be indicated according to following criteria in the IVUS-guided strategy arm~\*Criteria for revascularization: Minimum lumen area (MLA) ≤ 3mm2 or 3\< MLA ≤ 4mm2 \& Plaque burden \> 70%
Study: NCT03514615

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incision
Description: A skin incision will be made on the medial aspect of the upper arm.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Incision
Description: A skin incision will be made on the medial aspect of the upper arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active gel
Description: The incision site on one arm will be dosed with the active gel.
Study: NCT04424472

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Abdominal Ultrasonography
Study: NCT02956707

Intervention type: OTHER
Intervention: No pre-operative steroids
Description: Due to new information provide from previous studies at our center the investigator instituted a clinical practice change remove steroid administration in the pre-operative period for all neonates undergoing surgery with cardiopulmonary bypass. This study is to evaluate this change.
Study: NCT00452153

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Characterization Legionnella
Description: * Characterisation Legionnella by polymerase chain reaction (PCR)~* Characterization strain of Legionnella by sequencing the 23S-5S ribosomal intergenic spacer region
Study: NCT03514615

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: The incision site on the other arm will be dosed with placebo gel.
Study: NCT01378806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and exercise education and coping skills training
Description: A 12-week intensive intervention on nutrition and exercise education and coping skills (Phase I), 9 months of continued monthly contact (Phase II), and then 6 months on their own.
Study: NCT05869396

Intervention type: DIAGNOSTIC_TEST
Intervention: echocardiography
Description: Bedside echocardiography
Study: NCT04131582

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Linagliptin + metformin and Empagliflozin + metformin
Description: Linagliptin-Metformin 2.5/850mg once daily, Empagliflozin-Metformin 12.5/850mg one daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
Study: NCT02051088

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Revascularization with drug-eluting technology
Description: Endovascular intervention with the use of drug-eluting devices (drug-coated balloons and/or drug-eluting stents).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Revascularization without drug-eluting technology
Description: Endovascular intervention without using drug-eluting balloons or stents

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug-coated balloons and/or drug-eluting stents